Scynexis (SCYX) Cash & Current Investments (2013 - 2026)
Scynexis' (SCYX) quarterly Cash & Current Investments came in at $114.7 million in Q2 2026, up 42.9% on a YoY basis from $80.3 million in Q2 2025, and up 20.74% quarter-over-quarter from $95.0 million in Q1 2026.
Analysis
Scynexis (SCYX) Cash & Current Investments (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Cash & Current Investments for 14 consecutive years, with $114.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Current Investments rose 42.9% year-over-year to $114.7 million; the trailing twelve-month figure through Jun 2026 stood at $114.7 million (up 42.9% YoY), and the FY2025 full-year result was $40.0 million, down 32.49% from the prior year.
- Cash & Current Investments rose to $114.7 million in Q2 2026 per SCYX's latest filing, from $95.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $149.2 million in Q3 2023 and bottomed at $40.0 million in Q4 2025.
- Historically, Cash & Current Investments has averaged $98.3 million across 5 years, with a median of $95.1 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments soared 68.02% in 2024, then sank 51.17% in 2025.
- Over 5 years, Cash & Current Investments stood at $73.5 million in 2022, then increased by 1.17% to $74.4 million in 2023, then slipped by 20.25% to $59.3 million in 2024, then plunged by 32.49% to $40.0 million in 2025, then jumped by 186.52% to $114.7 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $114.7 million, $95.0 million, and $40.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.85 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 7.99 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 5.18 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.14 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 114.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 114.70 Mn |
| Mar 31, 2026 | 94.99 Mn |
| Dec 31, 2025 | 40.03 Mn |
| Sep 30, 2025 | 61.03 Mn |
| Jun 30, 2025 | 80.27 Mn |
| Mar 31, 2025 | 87.47 Mn |
| Dec 31, 2024 | 59.30 Mn |
| Sep 30, 2024 | 125.00 Mn |
| Jun 30, 2024 | 130.74 Mn |
| Mar 31, 2024 | 138.96 Mn |
| Dec 31, 2023 | 74.36 Mn |
| Sep 30, 2023 | 149.20 Mn |
| Jun 30, 2023 | 119.54 Mn |
| Mar 31, 2023 | 82.71 Mn |
| Dec 31, 2022 | 73.50 Mn |
| Sep 30, 2022 | 123.57 Mn |
| Jun 30, 2022 | 118.70 Mn |
| Mar 31, 2022 | 95.21 Mn |
| Dec 31, 2021 | 104.48 Mn |
| Sep 30, 2021 | 100.11 Mn |